Kihara James
Known title: Principal Accounting OfficerCIK: 0001816160
Associated companies
Transaction History
| ACAD | ▼ Sell | Open Market | 11,421 | $298K | 6/26/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,401 | $114K | 5/26/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,332 | $29K | 5/4/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,596 | — | 5/1/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,030 | $23K | 4/7/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,010 | — | 4/5/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,097 | $24K | 3/26/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 12 | $261 | 3/26/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 833 | $18K | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,142 | — | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,627 | — | 3/24/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 4,084 | $97K | 11/18/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,966 | — | 11/17/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,966 | — | 11/17/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,000 | $50K | 5/16/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,000 | $40K | 5/16/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,327 | $19K | 5/2/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,596 | — | 5/1/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,028 | $15K | 4/8/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,010 | — | 4/5/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,095 | $19K | 3/26/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,142 | — | 3/25/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 475 | $9K | 2/24/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 840 | — | 2/23/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 4,073 | $68K | 11/19/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,965 | — | 11/17/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,965 | — | 11/17/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,326 | $22K | 5/2/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,596 | — | 5/1/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,028 | $18K | 4/8/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 762 | $14K | 4/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,489 | — | 4/7/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,010 | — | 4/5/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 474 | $12K | 2/26/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 840 | — | 2/23/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,000 | $57K | 12/15/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,985 | $45K | 11/20/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,982 | — | 11/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,982 | — | 11/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,000 | $52K | 9/15/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,000 | $48K | 6/15/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,947 | — | 5/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,947 | — | 5/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,947 | $134K | 5/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 523 | $9K | 4/10/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,489 | — | 4/7/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 701 | $13K | 4/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,009 | — | 4/5/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 350 | $7K | 2/24/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 840 | — | 2/23/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,025 | $28K | 4/8/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,977 | — | 4/7/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 840 | $0 | 2/23/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 359 | $9K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.